Redox Dual‐Responsive Drug Delivery System with Cascade of Reactive Oxygen Species Self‐Generation for Enhanced Cancer Chemotherapy

View at publisher
Authors: Lingli Zeng, Ni Ding, Zhiyang Chen, Xin Zheng, Xi Liu, Hao Zhang, Xing Lv, Yining Wang, Youpeng Chen, Mei Hu, Yang Kang
Cited by: 1
References: 41

Abstract

Conventional chemotherapy is significantly hampered by the inherent hydrophobicity of chemotherapeutic agents, limited tumor-specific targeting, and inadequate intratumoral accumulation, all of which undermine its clinical efficacy. Nonselective distribution of cytotoxic agents leads to suboptimal drug concentrations within tumor tissues, causing systemic toxicity in healthy organs. Tumor microenvironment-responsive nanoplatforms offer a promising strategy for enhancing specificity and efficacy. This study demonstrates the successful development of a nanodrug delivery system, CASS@PTX nanoparticles, where CASS is a cinnamaldehyde-based, disulfide-containing polymer engineered with dual-stimulus responsiveness to glutathione (GSH) depletion and reactive oxygen species (ROS) amplification. This system disrupts intracellular redox homeostasis in tumor cells, triggering the release of encapsulated paclitaxel (PTX) while enhancing chemotherapeutic efficacy through redox-dependent sensitization. GSH consumption and ROS overproduction create a prooxidative microenvironment that enhances PTX-induced apoptosis. Preclinical validation using in vitro cytotoxicity assays and in vivo tumor models demonstrates potent synergistic anti-tumor effects with minimal systemic toxicity. This cascading ROS self-generation strategy represents a promising approach for overcoming multidrug resistance and improving the therapeutic outcomes of cancer chemotherapy.

Fields of Study & Subjects

Nanoplatforms for cancer theranostics Sulfur Compounds in Biology Nanoparticle-Based Drug Delivery

Publication details

Journal / source
Advanced Healthcare Materials
Publisher
Wiley
Volume
15
Issue
18
Pages
e71002–e71002
Publication date
4 March 2026
Language
EN